Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Alex. Brown analyst Kevin Tang downgraded GNSA to "neutral" from "buy" following the San Diego company's announcement that a setback in the scale-up of its Geomatrix nifedipine
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury